Skip to main content
. 2020 Dec 25;13(1):44. doi: 10.3390/cancers13010044

Figure 1.

Figure 1

Flowchart of HER2 testing of molecularly classified PORTEC-3 trial participants. * SISH was performed on a random selection of cases with absent (n = 10) and faint (n = 10) membranous staining to confirm the absence of HER2 amplification. Abbreviations: IHC, immunohistochemistry; SISH, silver in situ hybridization; NGS, next-generation sequencing.